Safety of a cytomegalovirus-specific hyperimmunoglobulin in the prevention of maternal-fetal transmission after primary infection-results of an open-label, single-arm, prospective trial.

Arch Gynecol Obstet · 2026 · PMC12789126 · PMID 41511637

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

did not reach statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

The number of obstetrical AEs (preterm delivery, preeclampsia, and fetal growth restriction) was higher in the CMVIG group, but did not reach statistical significance (13% CMVIG group vs. 2% placebo group, p = 0.06).

also in 111,027 other papers

showed a trendno p-value reported

Participants who received CMVIG showed a trend toward higher incidence of headaches and shaking chills while receiving infusions than participants who received placebo.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.